Related Topics News -

     
 Detail   |   Print 
     
復宏漢霖HLX14上市註冊申請獲國家藥監局受理
2026-09-11T  
《大行》花旗微升復宏漢霖目標價至95.2元重申「買入」 上半年自然增長穩固
2026-08-26T  
《業績》復宏漢霖中期純利4.3億人民幣 增長10.3%
2026-08-23T  
復宏漢霖與Sandoz達成全球戰略合作 今年開票金額料達1億美元
2026-08-17T  
復宏漢霖:HLX43聯合藥物治療獲批准內地臨床
2026-07-31T  
維立志博維利信用於一線治療晚期膽道癌II期臨床研究完成全部患者入組
2026-07-30T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.